Biotech IPOs are thawing, but M&A still drives the market
After more than 14 months of geopolitical turmoil and a prolonged stretch of macro stress, biotech looks more open than it has in years. Kailera Therapeutics' record-setting $625 million IPO and other upsized debuts have helped restore confidence that public-market appetite is returning.
The debate is real: this is not 2021, and the bar for companies to go public remains relatively high. But that should not be confused with a closed market. Even with an interest rate environment that has turned for the worse, deal activity is still moving forward.
So far this year, biotech deals have reached $106 billion across 201 transactions. More important, biopharma M&A is on pace for more than $250 billion in 2026. That is the figure that matters most for investors. A strong acquisition market does more than generate headlines; it expands exit routes and helps support valuations because strategic buyers are still willing to pay for pipeline fill-ins and patent-cliff protection.
If M&A stays this active, some of the best assets may get acquired before they have a chance to prove public-market durability. That makes the current setup more interesting than a simple IPO rebound: capital is already moving, whether through public listings or corporate deals.
The patent cliff is the main reason big pharma keeps buying
Loss of exclusivity is creating real revenue pressure
Big drugmakers still rely heavily on a small number of blockbuster drugs. When those patents expire, revenue can fall quickly unless replacement products are already in place.
By 2032, losses of exclusivity for best-selling brands are worth at least $173.9 billion in annual sales. For companies accustomed to steady cash flow, that is not a minor setback. It is a major revenue gap that has to be filled.
Acquisition is a growth-replacement tool
That helps explain why pharma dealmaking is not just financial theater. It is a way to replace lost growth.
The urgency is already visible in spending. In the first quarter alone, biotech M&A reached $84 billion. Reuters also reported that Keytruda generates more than half of the company's revenue for Merck and is set to face exclusivity loss in 2028, underscoring how quickly top-line pressure can build when a single drug supports most of the business.
That helps explain why investors should view this cycle carefully. M&A is being pulled by necessity. IPO activity, by contrast, still depends more on sentiment. Deadlines tend to keep checkbooks open longer than market mood swings.
What investors should watch in biotech now
The opening is real, but this is not a free-for-all. First-quarter biotech M&A already reached $84 billion, the sector's strongest start to a year since 2019. That is encouraging, but a healthier recovery is not defined by a few headline debuts alone. Investors still want strong clinical data, experienced management teams, and truly differentiated programs or technologies. Without those basics, a warmer market may improve financing conditions, but it will not automatically create a durable public-market winner.
The practical takeaway is simple: the best opportunities are likely assets that could appeal to both strategic buyers and public-market investors. One creates urgency. The other creates liquidity. If the recovery broadens, those companies can build value on their own. If it does not, they may still get acquired, though usually on terms set by the buyer rather than the public market.